AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
+0.45 (4.40%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.02 - 10.75
52 week 5.35 - 13.64
Open 10.45
Vol / Avg. 799,999.00/745,694.00
Mkt cap 459.66M
P/E     -
Div/yield     -
EPS -0.66
Shares 43.04M
Beta 1.69
Inst. own 87%
Jun 24, 2014
AcelRx Pharmaceuticals, Inc. at JMP Securities Healthcare Conference Add to calendar
Jun 2, 2014
AcelRx Pharmaceuticals, Inc. at Jefferies 2014 Global Healthcare Conference Add to calendar
May 20, 2014
AcelRx Pharmaceuticals, Inc. at UBS Global Healthcare Conference - 10:30AM EDT - Add to calendar
May 6, 2014
AcelRx Pharmaceuticals, Inc. at Mizuho Securities USA Healthcare Corporate Access Day Add to calendar
Apr 28, 2014
Q1 2014 AcelRx Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Apr 9, 2014
AcelRx Pharmaceuticals, Inc. at Needham Healthcare Conference - Webcast
Mar 11, 2014
AcelRx Pharmaceuticals, Inc. at ROTH Conference - Webcast
Mar 11, 2014
AcelRx Pharmaceuticals, Inc. at EBD BIO-Europe Spring
Mar 4, 2014
AcelRx Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Mar 3, 2014
Q4 2013 AcelRx Pharmaceuticals, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 64.36% -79.40%
Operating margin 72.38% -22.60%
EBITD margin - -20.59%
Return on average assets 74.75% -26.84%
Return on average equity 112.80% -43.78%
Employees 27 -
CDP Score - -


351 Galveston Drive
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company's products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Richard A. King President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D., Ph.D. Chief Medical Officer, Director
Age: 50
Bio & Compensation  - Reuters
David H. Chung Chief Commercial Officer
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 49
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Mike A. Royal M.D. Chief, Clinical Affairs
Age: 58
Bio & Compensation  - Reuters
Richard F. Afable M.D., Director
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 55
Bio & Compensation  - Reuters